SGT-1001 is the first development candidate using SalioGen’s…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
IN THE NEWS
04/16/2024
Nacuity Pharmaceuticals Expands Board of Directors with Appointment…
Ophthalmology industry veteran brings 20 years of experience…
03/26/2024
Opus Genetics Announces Completion of Dosing in First Cohort of Pha…
OPGx-LCA5 will advance to the next highest dose in mid-2024 …
02/15/2024
Nacuity Pharmaceuticals Announces Expansion of its Business Advisor…
FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity…
02/08/2024
SparingVision Presents Initial SPVN06 Safety Data at the Macula Soc…
• No serious adverse events in the first two cohorts of pat…
12/08/2023
ProQR Therapeutics Announces Transaction Completed for Théa to Acqu…
Divestment of sepofarsen and ultevursen completed – Théa to …
12/04/2023
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy…
ATSN-101 continues to demonstrate clinically meaningful impr…
11/14/2023
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced The…
RMAT designation recognizes the potential of ATSN-101 to add…
11/03/2023
New Preliminary Clinical Data on Potential of Opus AAV-based Gene T…
Data to be presented as part of gene augmentation therapy pr…
10/16/2023
The Retinal Degeneration Fund Announces an Investment in NVasc
NVasc is developing a therapeutic angiogenesis strategy for …
09/26/2023
SparingVision Selects Second Target in Strategic Collaboration with…
Milestone broadens partnership to develop novel ocular thera…
09/07/2023
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of G…
OPGx-LCA5 is designed to address vision loss due to Leber co…